ALX Oncology

Alx Oncology

Biotechnology, 323 Allerton Ave, South San Francisco, California, 94080, United States, 11-50 Employees

alxoncology.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 65********

Who is ALX ONCOLOGY

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridg...

Read More

map
  • 323 Allerton Ave, South San Francisco, California, 94080, United States Headquarters: 323 Allerton Ave, South San Francisco, California, 94080, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8733 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ALX ONCOLOGY

ALX Oncology Org Chart and Mapping

Employees

Andrew Olson

Senior Director, Portfolio Planning

Beatrice Chiang

Director of Clinical Safety Science

Mithu Sherin

Director of Intellectual Property

Julie Bacon

Senior Manager, Clinical Data Management

Kim Tipton

Senior Clinical Scientist

Mayank Rao

Medical Director, Clinical Development

Michael Chang

Vice President Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ALX Oncology

Answer: ALX Oncology's headquarters are located at 323 Allerton Ave, South San Francisco, California, 94080, United States

Answer: ALX Oncology's phone number is 65********

Answer: ALX Oncology's official website is https://alxoncology.com

Answer: ALX Oncology's SIC: 8733

Answer: ALX Oncology's NAICS: 541715

Answer: ALX Oncology has 11-50 employees

Answer: ALX Oncology is in Biotechnology

Answer: ALX Oncology contact info: Phone number: 65******** Website: https://alxoncology.com

Answer: ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncologys lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access